Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

周一，JMP Securities给予Summit Therapeutics plc (NASDAQ:SMMT)一个"市场表现优于大盘"的评级，目标价为$32.00。这一新的覆盖反映了对该公司最近从传染病转向肿瘤学的战略转变持积极看法。 这家生物制药公司在2022年进行了战略转型，从Akeso引进了ivonescimab，这是一种PD-1 x VEGF双特异性抗体。这笔交易包括5亿美元的预付款和高 ...

The company also has a solid dividend record. Its payouts have increased by 71% in the past decade, and it currently offers a ...

Crescent Biopharma is advancing a drug its CEO claims is “purpose-built” to be a perfected version of Summit Therapeutics’ ...

The latest update is out from Summit Therapeutics ( (SMMT) ).

The stock has risen over 600% since the end of 2023, thanks to surprisingly positive trial results for a cancer therapy called ivonescimab. The stock market has been pushing up Summit's stock ...